# Jiangsu Bioperfectus Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-bioperfectus-technology-co

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.bioperfectus.cn
- Latest round: Series A (Oct 19, 2016)
- Investors on record: 4

## About

Based in Taizhou, China and established in 2010, Jiangsu Bioperfectus Technology Co., Ltd. is a nucleic acid and protein detection product developer. It has a branch in Shanghai. It also has acquired High-Tech Enterprise Certificate. In March 2017, Jiangsu Bioperfectus Technology Co., Ltd. closed a venture funding from new investors Lyfe Capital and Tianyi Investment Group. In November 2019, It raised RMB 685.79 million in an IPO, selling 14.66 million share at RMB 46.78 per share on the Shanghai Stock Exchange.

The company's products mainly include biological technology platforms such as fluorescent quantitative PCR, biochips, and enzyme chemistry. It has developed products such as infectious disease pathogen detection, female reproductive tract microecology detection, and tumor screening.

The company generates revenue by developing molecular diagnostic technology and provides related products.

## Funding rounds

- Series A, Oct 19, 2016 — Weidu Capital
- Angel, Jun 2, 2015 — CID Group, LYFE Capital, Neovision Capital

## Investors

- CID Group (https://capitalatlas.ai/funds/cid-group) — Angel
- LYFE Capital — Angel
- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Angel
- Weidu Capital (https://capitalatlas.ai/funds/weidu-capital) — Series A